UCB, BE0003739530

UCB stock: BIMZELX peak-sales outlook reaches at least EUR 7 billion

Published on 11/18/2026 at 18:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock remains tied to a broader portfolio strategy after the Jefferies conference. Management pointed to neurology assets and further deal capacity.

UCB broadens its growth plan

  • Management presented BIMZELX as an anchor for growth while highlighting additional neurology and immunology opportunities.
  • The company said prescribing habits, rebates and step-edit rules have slowed the drug's commercial adoption.
  • Further acquisitions remain part of UCB's strategy as the company builds a broader portfolio.
UCB, BE0003739530, Illustration mit AI erstellt.

UCB stock traded at 285.95 euros on Lang & Schwarz at 18:08 CET on Wednesday, November 18. That compares with 296.85 euros in the company's previous report on Saturday, November 14, a change of -3.67 percent since that report.

At the Jefferies Global Healthcare Conference on Tuesday, November 17, Chief Executive Jean-Christophe Tellier presented BIMZELX as the anchor of a broader growth plan. Investing.com reported that management lifted peak-sales guidance for BIMZELX to at least 7 billion euros.

BIMZELX remains the growth anchor

UCB said BIMZELX has shown superiority against standard of care in four head-to-head trials spanning psoriasis and psoriatic arthritis. Management also said about 150,000 patients are receiving the medicine.

The commercial rollout has been slower than the clinical record might suggest. UCB pointed to established prescribing habits, pharmacy benefit manager rebates and step-edit rules as factors that can delay broader uptake.

Pipeline adds strategic breadth

The conference discussion placed the drug within a wider portfolio covering immunology, inflammation and neurology. UCB highlighted bispecific and T-cell engager programs, as well as efforts to move selected neurological treatments toward disease modification.

Management said BIMZELX patent protection runs to 2037 and that four additional growth drivers have protection into the early 2030s. UCB also said it retains capacity for further acquisitions, with future transactions expected to remain close to its existing areas of expertise.

UCB share facts

  • Company: UCB S.A.
  • ISIN: BE0003739530
  • Quote: 285.95 euros on Lang & Schwarz, November 18, 2026, 18:08 CET
  • Previous report quote: 296.85 euros on Lang & Schwarz, November 14, 2026, 12:39 CET

European healthcare shares remain an important backdrop for biotechnology companies; Current market reports track the broader trading environment.

More news and analyses on UCB stock

Disclaimer...
en | BE0003739530 | UCB | boerse | 70532067 | bgmi